NEWARK, N.J. (Legal Newsline) – The maker of a generic version of a recently recalled diabetes medicine faces a class action lawsuit.
Attorneys at four plaintiffs firms on Oct. 7 sued Amneal Pharmaceuticals over Metformin, a drug possibly containing NDMA. The Environmental Protection Agency lists NDMA as a probable human carcinogen.
The class action seeks damages and medical monitoring for class members.
“(F)or years, Defendant willfully flouted federal current Good Manufacturing Practices and ignored other warning signs that Defendants’ (Metformin-containing drugs) contained or likely contained NDMA and/or other impurities,” the lawsuit says.
The firms pushing this case, one of many over Metformin, are Golomb & Honik of Philadelphia, GoldenbergLaw of Minneapolis, Kanner & Whiteley of New Orleans and Levin Papantonio of Pensacola, Fla.